Cargando…
Substrate-specific binding and conformational changes involving Ser(313) and transmembrane domain 8 of the human reduced folate carrier, as determined by site-directed mutagenesis and protein cross-linking
RFC (reduced folate carrier) is the major transporter for reduced folates and antifolates [e.g. MTX (methotrexate)]. RFC is characterized by two halves, each with six TMD (transmembrane domain) α helices connected by a hydrophilic loop, and cytoplasmic N- and C-termini. We previously identified TMDs...
Autores principales: | Hou, Zhanjun, Wu, Jianmei, Ye, Jun, Cherian, Christina, Matherly, Larry H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947195/ https://www.ncbi.nlm.nih.gov/pubmed/20557288 http://dx.doi.org/10.1042/BJ20100181 |
Ejemplares similares
-
Post-transcriptional regulation of the human reduced folate carrier as a novel adaptive mechanism in response to folate excess or deficiency
por: Hou, Zhanjun, et al.
Publicado: (2014) -
The evolving biology of the proton‐coupled folate transporter: New insights into regulation, structure, and mechanism
por: Hou, Zhanjun, et al.
Publicado: (2022) -
The human proton-coupled folate transporter: Biology and therapeutic applications to cancer
por: Desmoulin, Sita Kugel, et al.
Publicado: (2012) -
Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer
por: Wallace-Povirk, Adrianne, et al.
Publicado: (2021) -
Folate transporter dynamics and therapy with classic and tumor-targeted antifolates
por: O’Connor, Carrie, et al.
Publicado: (2021)